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SUMMARY
Background
As treatments for constipation become increasingly available, it is important to
know when to progress along the treatment algorithm if the patient is not better.
Aim
To establish the deﬁnition of failure of a treatment to provide adequate relief
(F-PAR) to support this management and referral process in patients with chronic
constipation.
Methods
We conducted an international Delphi Survey among gastroenterologists and gen-
eral practitioners with a special interest in chronic constipation. An initial ques-
tionnaire based on recognised rating scales was developed following a focus group.
Data were collected from two subsequent rounds of questionnaires completed by
all authors. Likert scales were used to establish a consensus on a shorter list of
more severe symptoms.
Results
The initial focus group yielded a ﬁrst round questionnaire with 84 statements.
There was good consensus on symptom severity and a clear severity response
curve, allowing 67 of the symptom-severity pairings to be eliminated. Subsequently,
a clear consensus was established on further reduction to eight symptom state-
ments in the ﬁnal deﬁnition, condensed by the steering committee into ﬁve diag-
nostic statements (after replicate statements had been removed).
Conclusions
We present an international consensus on chronic constipation, of ﬁve symptoms
and their severities, any of which would be sufﬁcient to provide clinical evidence
of treatment failure. We also provide data representing an expert calibration of
commonly used rating scales, thus allowing results of clinical trials expressed in
terms of those scales to be converted into estimates of rates of provision of
adequate relief.
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INTRODUCTION
Chronic constipation (CC) is a common condition which
is very prevalent in many societies.1, 2 A particular chal-
lenge of chronic constipation is that the various symp-
toms can mean radically different things to different
people. Furthermore, the range of symptoms inﬂuences
the choice of treatment and the perception of beneﬁt.3
Most patients with CC treat their condition by modify-
ing their diet and lifestyle or with OTC remedies.4
Patients consult healthcare professionals when these
measures fail. Subsequent medical intervention usually
involves the rational use of laxatives5, 6 but surveys show
that treatment satisfaction among patients is low.7–9
The emergence of new pharmacological treatment
options,10–14 some of which are predominantly initiated
in secondary care settings, has led to the need for guid-
ance on when newer expensive or invasive treatments
should be offered.
Some of these newer treatments are medications
which could conceivably be initiated in primary care if it
could be conﬁrmed in that setting that standard treat-
ments, such as laxatives, had failed to provide adequate
relief. Other newer treatments are nonpharmacological
in nature, such as sacral neuromodulation and pelvic
ﬂoor surgery. These are only available in secondary care
and a reliable deﬁnition of failure of treatment to pro-
vide adequate relief is critical for deﬁning progression
through the algorithm of care.15 Therefore, there is a
need for an expert deﬁnition of F-PAR in CC, ideally
based on patient reported outcome measures (PROMs),
similar to those reported recently for opiate related con-
stipaton.16, 17 And meeting this need is important
because it is only when ﬁrst line treatments have failed
to provide adequate relief that second line and secondary
care treatment options can be justiﬁed.
There are several methods of obtaining expert consen-
sus opinion (Grade IV evidence) in the absence of
deﬁnitive results from clinical trials, however, most of
these depend on subjective review and group discussion
methods, which are open to inﬂuence and bias. An alter-
native approach is to use Delphi Surveys.
Delphi Surveys are carried out by sending question-
naires to experts who complete them in private free from
any external inﬂuence. The results of Delphi surveys are
subsequently analysed using descriptive statistics18–20 in
keeping with rigorous scientiﬁc methodology. Such a sci-
entiﬁc method is likely to be able to establish the true
balance of expert opinion and for this reason has been
used extensively to support guideline development in
medicine. For example, the German Gastroenterology
Guideline on irritable bowel syndrome21 and the 2012
Consensus statement on the management of Barrett’s
dysplasia of the oesophagus were also developed using
Delphi methodology.22 The same approach was also used
to deal with areas of uncertainty in developing the Rome
IV criteria.23
The aim of this Delphi Survey was to reach an expert
consensus on the clinical features required to deﬁne F-
PAR in CC, which could also be used as the basis for a
decision support tool for use by family doctors and other
healthcare professionals who see the majority of patients
with chronic constipation.
METHODS
Consensus of experts and the Delphi method
The Delphi Survey technique has been used widely in
medical and nursing research as a method to obtain a
consensus among a group of experts.19 The technique
involves a panel of about twenty experts taking part in
an iterative process in which a series of questionnaires is
completed by each of them independently in private.
The results of each round are presented back to them
only in a summary and in an anonymised form.
The results of one round are used to determine which
remaining or modiﬁed questions are asked in the next
round with each consecutive round of questions worded
to facilitate an increasing degree of consensus until 75%
or 80% of participants agree on each proposition
remaining in the process.19 Because the questionnaires
are completed in private and because the results are only
fed back in a summary anonymised form, the process is
not open to inﬂuence by overt peer pressure from the
other participants.19 The risk of bias can also be reduced
if an independent facilitator, unconnected with the par-
ticipants, is appointed to run the methodological side of
the project including drafting the questionnaires and
analysing the results.19
A consensus can only be said to be achieved when a
pre-determined proportion of participants are in agree-
ment. This proportion varies between studies and also
depends on the way the questionnaires are constructed.
Thus, median values may be used as cut-off points in
continuous or ordinal data, but, where Likert scales are
used, it is customary to require 75% or 80% of partici-
pants to rate a proposition as one they agree with or
agree strongly with in order for a consensus to exist on
that point.19
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In the case of this study, the ﬁnal consensus was
based on an 80% level of agreement.
Participants
The participants in this Delphi survey were European
experts in CC. The potential participants were identiﬁed
based on their publishing record, their established clini-
cal expertise in CC, and their seniority in their place of
work (academic institution, secondary or tertiary care
hospital). Clinicians for consideration were proposed by
the various participants in the study, also including the
study sponsor (Shire International GmbH).
Once participants accepted the invitation to take part
they were referred to a Clinical Research Organisation
(CRO) which provided the independent study logistics
and supported the activities of the Independent Facilitator.
The role of the sponsor was limited to: proposing partici-
pants, providing funding for the logistics and for hono-
raria to be paid to the steering committee members and
the study participants (all at fair market rates). No pay-
ments were made in relation to the writing of this manu-
script. The sponsor reviewed the study protocol developed
by the Independent Facilitator after it was signed by Steer-
ing Group members (but proposed no changes).
The steering group (n = 5) had three functions: (i) to
provide the Facilitator with a source of extensive expert
opinion from which to generate the initial Delphi question-
naire (ii) to advise the Facilitator about technical matters of
fact in relation to the study results at the end of each round
and any implications these ﬁndings have for the design of
the questionnaire for the next round and (iii) to vote in each
round of the study by completing the same Delphi question-
naires as those completed by the panellists (n = 15).
The panellists (n = 15) had one main function: (i) to
complete and return each round of Delphi question-
naires as they were e-mailed to them.
A list of the names of the participants in the panel
and steering group is given in the appendix and all are
listed as authors.
Study duration
The time required to draft the study protocol, recruit the
steering group and panel members, run the study and
analyse the data was 4 months.
Initial focus group
The initial round of any Delphi Study is designed to gather
as many examples of expert opinion on the study subject
as possible. In this study the initial round was conducted
by running a focus group involving the Steering Group
members (Modiﬁed Delphi method as described by
Keeney).19 The Steering Group members were asked to
provide as many examples of CC symptoms, CC rating
scales and CC clinical checklists as possible to use as raw
material for making the questionnaires to be used in the
voting stage of the Delphi Study.
A full list of the questions included in each round of
the Delphi Survey is included in data Table 1.
A decision was made to build the consensus in two
parts owing to the wide range of possible clinical options
for deﬁning ‘failure of a treatment to provide adequate
relief for chronic constipation’.
The ﬁrst part of the consensus building addressed
the degree of severity of CC symptoms required for
them to count as failure to provide adequate relief.
This identiﬁed symptom-severity pairs which a major-
ity of the participants accepted as providing evidence
of F-PAR of CC.
The second part of the consensus building addressed
which of the symptom-severity pairs accepted as evi-
dence of F-PAR of CC were most appropriate for inclu-
sion in the ﬁnal deﬁnition of the Expert Consensus.
STUDY FLOW
Phase one: output of focus group
Based on the material gathered during the focus group the
Facilitator prepared a questionnaire for the ﬁrst round of
the Delphi Survey. The questionnaire had 84 propositions
and was reviewed and approved by the Steering Group
prior to use. The 84 propositions were framed either as
reported patient statements or as diagnostic descriptions.
The propositions were to be scored using a ﬁve point Lik-
ert rating scale ranging from Strongly Disagree to Strongly
Agree. To avoid any bias due to questions derived from
the same rating scale being asked sequentially (and there-
fore answered on the basis of pre-conceived views about
the meaning of that scale), the order in which the ques-
tions were presented was randomised. The questionnaires
were sent to the Steering Group and Extended Panel mem-
bers to be completed and returned electronically.
Simple descriptive statistics were calculated for each
question. For tabulation, the results were grouped by
questions derived from the same rating scale or checklist
and then graphs were plotted to compare severity of
symptom to level of acceptance as F-PAR. Where a med-
ian value of 4 or more for the Likert score was recorded,
the symptom-severity pair was accepted as providing evi-
dence of F-PAR. Missing data were coded as ‘neither
agree nor disagree’.
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Phase two: generating a narrower questionnaire
The Facilitator presented the analysis of the ﬁrst round
questionnaires to the Steering Group. Based on their
advice a second round questionnaire was developed
and approved in the same way as the ﬁrst round
questionnaire. This questionnaire focussed on deter-
mining which of the most highly rated F-PAR symp-
tom-severity pairs from round one had at least 80% of
participants scoring it agree or agree strongly (4 or 5
on the Likert scale). The round two questionnaire
comprised 17 propositions and these were also pre-
sented in random order. It was distributed, completed
and analysed in the same way as the ﬁrst round ques-
tionnaire.
Phase three: drafting and approval of the consensus
statement
The Facilitator presented the results of the second round
questionnaire to the Steering Group who conﬁrmed the
results and edited the questionnaire wording into a for-
mat suitable for use as a consensus statement and for
use as a check list or clinical decision support tool
(F-PAR Tool).
RESULTS
The results comprise three sets of information, presented
in sequence below.
Phase one: output of focus group
The output of the initial focus group was the raw mate-
rial from which the Facilitator designed the round one
questionnaire. The questionnaire was therefore based on
an extensive candidate list of CC symptom-severity pairs
including items derived from the PAC-SYM rating
scale24 and the Bristol Stool Scale (BSS).25 This part of
the process resulted in an initial questionnaire made up
of 84 propositions.
Phase two: generating a narrower questionnaire from
phase one
The results from the initial questionnaire of 84 proposi-
tions (presented to the panellists in a randomised order)
are presented in Table S1 and Figure S1, grouped the-
matically.
It should be noted that symptoms which are not
speciﬁc to CC were rated less favourably as evidence of
F-PAR than symptoms which form part of the ROME
III criteria for CC.26 A clear severity/response relation-
ship is apparent in Figure S1 with the more severe symp-
toms being accepted more strongly as being evidence of
F-PAR.
The output of the steering committee review of the
Round One results determined the items that went into
the Round Two questionnaire. In this way, 67 of the ini-
tial 84 questions (symptom – severity pairs) posed in
Table 1 | Final round results: round two questionnaire results
Question Median % agree/agree strongly
(a) At least 80% consensus
F-PAR = patient wishes to stop Rx because of symptom(s) 4 93%
F-PAR = strains excessively on most occasions 4 93%
F-PAR = more straining than previously (worsening) 5 87%
F-PAR = abdominal symptoms of CC not improved on current Rx 4 87%
F-PAR = no change in BSS on current Rx and BSS is 1 or 2 4 87%
F-PAR = patient wishes to stop Rx because of side effect(s) 5 80%
F-PAR = inadequate N bowel movements (P) and < 3/7 per week 4 80%
F-PAR = patient having to strain on most occasions 4 80%
(b) Less than 80% consensus
F-PAR = more abdominal symptoms than previously (worsening) 4 73%
F-PAR = toileting at least 15 min and longer or same as before 4 73%
F-PAR = worsening in BSS on current Rx and BSS is 1 or 2 4 73%
F-PAR = worsening of CC symptoms (P) since Rx started 4 73%
F-PAR = a lot of straining + impact on ADL 4 67%
F-PAR = CC symptoms made worse by current Rx 4 67%
F-PAR = CC symptoms made worse by current Rx 4 67%
F-PAR = inadequate N bowel movement days (P) + frequent straining 4 67%
F-PAR = inadequate N bowel movement days (P) + frequent straining 4 67%
F-PAR = inadequate N bowel movement days (P) + stool hard 4 67%
F-PAR = inadequate N bowel movement days (P) + stool hard 4 67%
F-PAR = toileting at least 15 min 3 40%
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Round 1 were eliminated rapidly from further considera-
tion as candidates for inclusion in a consensus deﬁnition
of F-PAR. As a result, the questionnaire for the next
round only comprised 17 propositions.
Phase three: drafting and approval of the consensus
statement
The results of the round two questionnaire made up of
17 propositions are given in Table 1. The cut-off for
accepting a consensus in support of a statement was
80% of the panel rating it ‘agree’ (scored as 4) or ‘agree
strongly’ (scored as 5). A total of eight statements met
this requirement for a consensus, but it should be noted
that there was some overlap in the content of these state-
ments. The steering committee therefore condensed the
overlapping text into a ﬁnal consensus deﬁnition of F-
PAR made up of the following ﬁve statements (consen-
sus checklist or F-PAR Tool):
Considering the situation over the last 2 weeks, if any
one of the following ﬁve statements applies to the patient
the current treatment for chronic constipation has failed
to provide adequate relief:
(i) An inadequate number of bowel movements is
reported by the patient most of the time AND complete
bowel movements occur on less than 3 days per week.
(ii) The patient have to strain on most occasions (or
straining is getting worse).
(iii) There is no improvement in the stool consistency
on current therapy AND the Bristol Stool Scale score is
less than 3 (hard and lumpy or very hard and small).
(iv) The patient reports insufﬁcient improvement of
another sign or symptom of chronic constipation on the
current treatment.
(v) Poor tolerability of the current treatment makes
the relief provided unacceptable to the patient.
It should be noted that the term ‘no improvement’
also included ‘worsening’.
The consensus statement was also presented in the form
of a questionnaire to be used as a Patient Reported Out-
come Measure (PROM), which we have termed the ‘F-
PAR Tool’ (Figure 1). This simple one page questionnaire
has been designed to be used as a self-reported patient
questionnaire and a treatment decision support tool.
DISCUSSION
This Delphi Survey reached an expert consensus on the
ﬁve key clinical features required to deﬁne the failure of
any given treatment to provide adequate relief for a
given patient with chronic constipation.
The ﬁve-item F-PAR tool, based on the ﬁve compo-
nents of the consensus statement, is proposed for use as
a clinical decision-making tool by gastroenterologists,
family doctors and other healthcare professionals who
treat patients with chronic constipation. Use of the pro-
posed F-PAR tool may make it possible to standardise
the process of conﬁrming the failure of a treatment to
provide adequate relief of CC, and may improve the
quality of treatment decision-making.
Although diagnostic criteria have existed for some
time for functional gastrointestinal disorders,26 establish-
ing the correct diagnosis and identifying aetio-pathogen-
esis of CC are key ﬁrst steps required to optimise the
clinical outcome for the patient. As new research has
provided a better understanding of the range of primary
and secondary causes of CC, so it has also identiﬁed new
targets for physical and pharmacological treatment of the
disease.27–30 With new behavioural, pharmacological and
surgical treatments becoming available it is essential to
recognise when a treatment is failing to work adequately
and thus should be switched. As a consequence, it has
become desirable to have an authoritative method for
deciding when a change in treatment is justiﬁed. We
think that the F-PAR consensus that was achieved in our
study supplies this need.
It may be objected that the use of a survey methods
to develop a consensus means that the consensus lacks
authority, however, the make-up of our study group sug-
gests otherwise. Furthermore, the consensus was
achieved after only two rounds of questionnaires, indi-
cating the strength of support for the deﬁnition of F-
PAR in CC among experts from across Europe and
among clinicians working in different clinical settings. It
also indicates the strength of support for, and the recog-
nition awarded to the need for, a deﬁnition of, F-PAR.
In summary, this working deﬁnition of F-PAR provides
an authoritative clinical method for deciding when a
change in treatment is justiﬁed.
The F-PAR tool has several strengths: ﬁrst, the way F-
PAR is deﬁned allows a key symptom for the patient to be
expressed and followed; second, the tool is easy to use,
requiring only one positive answer out of a total of ﬁve sim-
ply posed questions to be recorded as evidence of F-PAR.
Despite this simplicity, the F-PAR tool allows identiﬁcation
of individual symptoms beyond the typical (infrequency,
straining and stool consistency) as well as potential intoler-
ance of treatments used to date. As such, failure to respond
can be captured in the widest sense, for all patients.
This Delphi Survey also provides some useful insights
into how Delphi Surveys can be made more efﬁcient
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and rigorous. Delphi Surveys require iterative voting on
sequential versions of statements or questionnaires
meaning that they often take a long time to complete.
To meet the challenge of how to obtain a consensus
rapidly using a Delphi Survey, we undertook two adap-
tations to the classical methodology. The ﬁrst adaptation
was to build the consensus in two parts. In the initial
focus group stage, the Delphi process sought the widest
range of possible clinical options for deﬁning failure of
a treatment to provide adequate relief not only in terms
of the choice of symptoms but also in terms of their
severity. From the wide range of possible symptoms,
and the range of possible severities, it is clear that the
number of possible combinations of symptoms and
severities which could be tested as possible deﬁnitions of
F-PAR would be very large. Obtaining a consensus by
iterative voting on these would have required a large
number of rounds of voting. To reduce the number of
possible combinations in testing at any one time, we
sought consensus on sign and symptom severity before
seeking a consensus on sign and symptom choice. As
was reported above, the study was completed in only
4 months and this suggests that the sequential approach
to establishing a consensus allowed the result to emerge
rapidly.
The order of testing also provided an interesting
beneﬁt. The scientiﬁc interest of the ﬁrst round result
is considerable as they represent an expert derived
AnswerQuestion
Do you think the number of bowel movements you are having is OK? Yes/No 
Yes/No 
Yes/No 
On how many days did you have a complete bowel movement last week? [___] 
Are you having to strain on most occasions?2A
1A
1B
Is your straining getting worse?2B
3A
3B
Has there been any improvement in the hardness of your stools? Yes/No 
Please circle the number of the picture that matches most of your stools
7 
6 
5 
4 
3 
2 
1 
Do you want to stop treatment because of a symptom not given above? Yes/No 
If so, what is that symptom?4B
4A
_______________________
5A
5B
How do you rate the tolerability of your current treatment? Good/Poor 
If poor, is the benefit your current treatment gives you worthwhile? Yes/No 
Figure 1 | F-PAR questionnaire.
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calibration of adequate relief of CC in terms of symp-
tom severity measured by criteria which were drawn
from widely used rating scales such as the PAC-SYM
and Bristol Stool Scales. These calibration results could
be used in health economic studies to convert trial
results into outcomes (numbers with or without ade-
quate relief).
The second adaptation was to present the propositions
in the two Delphi questionnaires in a randomised order
such that propositions derived from the same rating
scale were not adjacent to each other when the question-
naire was being completed. This meant that the experts
were not doing the equivalent of completing the rating
scale as they answered the questionnaire, but were
obliged to address each proposition in isolation. As a
result, answer to each question was the result of careful
consideration rather than a reﬂection of preconceived
ideas about good and bad outcomes on familiar rating
scales.
Finally, an important observation is that the ﬁve fea-
tures of chronic constipation which remained after test-
ing in the second round closely resembled the key
symptom list, which is used to establish a diagnosis of
chronic functional constipation using the Rome III crite-
ria in force when the study was conducted,26 and also
the most recent version of the Rome criteria in force
when the study was accepted for publication,31, 32 which
are based on an evidence based knowledge but consensus
method (‘Delphi approach’),23 exactly the same method
we used in our F-PAR in CC study. This is an important
outcome as it ensures that the deﬁnition of F-PAR pro-
duced by our Delphi Survey is speciﬁc to chronic consti-
pation, being closely linked to the key, validated
diagnostic criteria for the condition.
We think that the F-PAR in CC tool has great poten-
tial of usefulness in clinical practice, by allowing accurate
identiﬁcation of patients who require a change in treat-
ment. Indeed, the way the consensus statement is framed
makes it easy to use it as a patient completed clinical
check list or as a clinical decision support tool. It is suit-
able for use in secondary but also in primary care, to
decide if a patient should be referred to secondary care
for an expert opinion on the future direction of treat-
ment or for more sophisticated testing that might be
required to establish the most appropriate choice of sec-
ond line treatment.
A validation study of the new tool in a clinical prac-
tice setting is the essential next step to conﬁrm the clini-
cal reliability and potential utility of the F-PAR tool.
Such studies are already ongoing.
In summary, the Delphi Survey reported in this paper
provided a rapid and robust route to obtaining a credible
and clinically relevant deﬁnition of F-PAR in CC. The
deﬁnition obtained is worded in a way which will make
it easy to use as a clinical check list or clinical decision
support tool when determining if a treatment for CC
should be changed, or if a patient with CC should be
referred for investigation in secondary care.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article:
Table S1. Round 1 results. (a) Proposition framed as a
question to the patient with their answer. (b) Proposi-
tions made as statements.
Figure S1. Round 1 results showing severity vs. med-
ian panel rating on Likert scale (4 & 5 = F-PAR) with
results ordered by severity within themes.
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APPENDIX 1
CLINICAL EXPERT PARTICIPANTS
AND THEIR COMPLETE
AFFILIATIONS
Prof. Jan Tack, Professor of Internal Medi-
cine, Department of Gastroenterology,
University Hospital Leuven, Herestraat 49,
3000 Leuven, Belgium (Study Steering
Group). Prof Peter Layer, Professor of Medi-
cine, Israelitisches Hospital, Medizinische
Klinik, Orchideenstieg 14, 22297 Hamburg,
Germany (Study Steering Group). Prof
Ingolf Schiefke, Klinik f€ur Gastroenterologie
und Hepatologie, Department of Internal
Medicine II, University of Leipzig, 04103
Leipzig, Germany (Study Steering Group).
Prof David Jayne, Professor of Surgery &
Honorary Consultant Surgeon, St. James’
University Hospital, Leeds LS9 7TF, UK
(Study Steering Group). Dr Anton Emma-
nuel, Consultant Gastroenterologist, Univer-
sity College Hospital, 235 Euston Road,
London NW1 2BU, UK (Study Steering
Group). Prof Richelle Felt-Bersma, Vrije
Universiteit Medisch Centrum, De Boelelaan
1117, 1081 HV Amsterdam, Postbus 7057,
1007 MB Amsterdam, Netherlands
(Extended Panel). Prof Danny De Looze,
Dept Gastroenterologie, Universiteit Gent,
De Pintelaan 185, B-9000 Gent, Belgium
(Extended Panel). Prof Asbjørn Mohr-
Drewes, Department of Clinical Medicine,
Medicinsk Center, Aalborg Sygehus,
Mølleparkvej 4, 9100, Aalborg, Denmark
(Extended Panel). Prof Philippe Ducrotte,
Professor of Gastroenterology, CHU-
Ho^pitaux de Rouen, 1 Rue de Germont,
76031 Rouen Cedex, France (Extended
Panel). Prof Thomas Frieling, Helios Klini-
kum Krefeld, Lutherplatz 40, 47805 Krefeld,
Germany (Extended Panel). Priv. Doz. Dr
Christian Pehl, Chefarzt Medizinische Kli-
nik, Krankenhaus Vilsbiburg, Kranken-
hausstr. 2, 84137 Vilsbiburg, Germany
(Extended Panel). Dr Torsten Hoheisel,
Facharzt f€ur Innere Medizin und Gastroen-
terologie, Ruhrallee 81, 45138 Essen, Nor-
drhein-Westfalen, Germany (Extended
Panel). Dr Andreas Leodolter, Sana-Klini-
kum Remscheid GmbH, Klinik f€ur Gas-
troenterologie, Hepatologie, Stoffwechsel-
und Infektionskrankheiten, Burger Straße
211, 42859 Remscheid, Germany (Extended
Panel). Prof Vincenzo Stanghellini, Depart-
ment of Gastroenterology, St. Orsola-Mal-
pighi Hospital, Via Massarenti 9, 40138
Bologna, Italy (Extended Panel). Prof Car-
melo Scarpignato, Laboratory of Clinical
Pharmacology, Division of Gastroenterology,
Department of Clinical Sciences, University
of Parma, Italy (Extended Panel). Dr
Constanza Ciriza de los Rios, Department of
Gastroenterology, Hospital 12 de Octubre,
Avda de Cordoba s/n, Madrid, 28041, Spain
(Extended Panel). Dr Enrique Rey, Profesor
Asociado de Medicina, Servicio de Digestivo,
Unidad de Motilidad, Hospital Clınico San
Carlos, Universidad Complutense, Madrid,
Spain. (Extended Panel). Prof. Magnus
Simren, Avd f€or inv€artesmedicin, Institutio-
nen f€or Medicin, Sahlgrenska Akademin,
G€oteborgs Universitet, 41345 Gothenburg,
Sweden (Extended Panel). Prof. Shaheen
Hamdy, School of Translational Medicine
(Inﬂammation Sciences), Faculty of Medical
and Human Sciences, University of Manch-
ester, Salford Royal Hospital, Eccles Old
Road, Salford M6 8HDUK (Extended
Panel). Dr Mark Fox, NIHR Biomedical
Research Unit, Nottingham Digestive Dis-
eases Centre, Queen’s Medical Centre, Not-
tingham NG7 2UH, UK (Extended Panel).
Dr Kathryn Gill – Consultant Surgeon,
Sandwell and West Birmingham Hospitals
NHS Trust, Sandwell Hospital, Lyndon,
West Bromwich B71 4HJ, UK (Extended
Panel). Dr Jamie Dalrymple, Chair at Pri-
mary Care Society for Gastroenterology,
Honorary Senior Lecturer at University of
East Anglia, GP partner, Drayton and St
Faiths Medical Practice, Horsham St Faith,
Norwich NR10 3LB, UK (Extended Panel).
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